TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
2期
已完成
NCT00694629
| 适应症 | Pulmonary Tuberculosis |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Centers for Disease Control and Prevention |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 334 人 |
|---|
| 干预（药物） | rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg |
|---|
| 开始日期 | 2008年12月 |
|---|
| 完成日期 | 2013年6月 |
|---|
| 结果公布日 | 2026年7月23日 |
|---|
摘要
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.
Participants With Negative Sputum Culture at 8 Weeks
8 weeks. · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 52 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 62 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 59 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 54 participants |
|---|
Participants Who Discontinued Treatment During Intensive Phase
8 weeks · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 11 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 9 participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。